International Biotechnology Trust PLC (IBT:LSE) reported strong performance for the year ended 31 August 2025, marking its fourth consecutive fiscal year of outperformance versus the NASDAQ Biotech Index. The fund achieved a total NAV per share return of 0.7% and a 3.8% return from its quoted portfolio, compared with a 6% decline in the benchmark. The trust maintained a 4.7% dividend yield and narrowed its share price discount from 11.3% to 8.9%, supported by over 3 million shares repurchased during the period. Co-lead fund managers Elsa and Marek highlighted five M&A transactions in the fiscal year and nine in the calendar year, reinforcing optimism for continued consolidation in the biotech sector. They noted that the reduction of management fees on the quoted portfolio to 65 basis points further enhances shareholder value. The managers discussed strategic gearing during sector lows in April, capitalising on recovery momentum and M&A activity. Approximately half the portfolio is invested in clinically de-risked assets, with an increased focus on rare diseases and smaller-cap biotech companies offering attractive valuations and acquisition potential. IBT’s diversified, actively managed portfolio is designed to capture upside in late-stage biotech while mitigating binary event risk. The trust’s positive outlook is underpinned by sector fundamentals, including a $100 billion patent cliff facing major pharma by 2028, driving acquisition demand. Backed by Schroders and over three decades of biotech investment expertise, IBT continues to deliver consistent NAV growth, stable yield, and defensive exposure to innovation-driven life sciences opportunities.

Amazing AI PLC (AQSE:AAI) delivered an investor presentation highlighting its dual focus on scalable lending operations and a high-leverage digital asset treasury strategy designed to maximise upside while managing downside risk. Founder and CEO Paul Mathieson, who also provides an undrawn £5 million debt facility, outlined the company’s evolution from traditional lending under its fully regulated U.S. subsidiary, Mr. Amazing Loans, to its current push into AI-driven financial technology and digital assets. The group, which reports gross margins of around 60% from its core lending business, operates with advanced automation enabling expansion to £100 million in loans without additional staff. Its new digital asset treasury, held via Amazing AI Services in Mauritius and custodied by BitGo, deploys sophisticated derivative structures offering 100× exposure for minimal cost, targeting Bitcoin, Ethereum, XRP, Solana, and gold-backed tokens. Matheson emphasised that this institutional-level strategy, unavailable to retail investors, combines high-margin lending with leveraged digital exposure for asymmetric growth potential. The company expects full deployment of its strategy by December 2025, backed by experienced leadership including Chairman Neil Patrick. With plans to license proprietary AI underwriting technology, expand globally, and pursue acquisitions of undervalued digital treasury peers, Amazing AI PLC aims to build a diversified fintech platform blending regulated consumer lending with advanced AI and blockchain innovation.

Conduit Holdings Limited (CRE:LSE) delivered a solid Q3 2025 trading update, reporting 8.5% year-on-year growth in gross premiums written to $1.04 billion, driven primarily by its casualty segment, which rose 20% to $269 million. Property premiums increased 6% to $568 million and specialty saw stable 2% growth to $202 million, reflecting disciplined underwriting amid a moderating rate environment. CEO Neil Eckert and CFO Elaine Whelan highlighted Conduit’s focus on underwriting quality and portfolio alignment as market competition intensifies following several years of rate hardening. Risk-adjusted rate changes were down 3% overall, with property and specialty softening, while casualty maintained positive momentum. The company reaffirmed mid-single-digit ROE guidance for 2025, supported by a strong investment portfolio yielding a 5.4% return year-to-date on $2 billion of managed assets. Conduit continues to strengthen its leadership team, appointing Stephen Postlewhite as Chief Underwriting Officer and Nicholas Shott as Independent Non-Executive Director, alongside internal promotions to enhance underwriting and risk management capabilities. The company is resuming its $50 million share buyback programme after the hurricane season, reflecting a balanced capital management approach. As Conduit prepares for 2026 renewals, it expects growth to moderate further while focusing on repositioning towards more excess-of-loss property business and reducing exposure to margin pressure in competitive lines. The company remains well-capitalised and committed to delivering resilient, long-term shareholder returns through disciplined underwriting, stable investment performance, and strategic talent investment.

Braemar PLC (BMS:LSE) delivered a resilient performance for the first half of FY25 despite weaker chartering markets and geopolitical headwinds, underlining the strength of its diversified model and disciplined execution. CEO James Gundy and CFO Grant Foley reported group revenue of £63.9 million, down 16% year-on-year (13% in USD) due to softer tanker rates and longer voyage times, while underlying operating profit before acquisition-related items fell 29% to £5.6 million, with a 9% margin. The forward order book rose from $73.8 million in August to $81.2 million in September, giving management confidence in the full-year outlook. The risk advisory (securities) division continued to outperform, with revenues up 9% and now contributing 20% of group turnover, supported by the UK Organised Trading Facility (OTF) going live and progress toward EU and Dubai licences. The company declared an interim dividend of 2.5p and maintained net debt of £5.6 million at period end, returning to a net cash position in October. Strategic initiatives continue to focus on diversification, global expansion, and operational excellence, including a new Cape Town office and further geographic and service line growth. Braemar reaffirmed its FY26 guidance and medium-term targets of £200 million revenue and a 15% operating margin by FY30, underscoring confidence in long-term growth, a strengthened forward order book, and improving freight market fundamentals.

EnSilica PLC (ENSI:LSE) reported audited full-year results for the 12 months ended 31 May 2025, marking a year of strategic progress, contract wins, and continued momentum across its semiconductor design and supply operations. The fabless semiconductor specialist, focused on mixed-signal ASICs for space communications, automotive, and industrial markets, secured six major NRE design contracts and strengthened its position in the European semiconductor value chain. FY25 revenue declined to £18.2 million due to project delays and the SEA contract suspension, but chip supply revenue nearly doubled, up 97%, highlighting scalability in its annuity-based model. Gross margins rose to 40%, EBITDA broke even, and a £6 million Lloyds Bank of Scotland refinancing bolstered liquidity for £5.8 million of R&D investment. The order book stands at £40 million in contracted NRE income through FY27 and £250 million in lifetime supply value, supported by a £400 million pipeline of opportunities. Management expects to achieve monthly cash flow positivity during 2026, driven by new contracts and a stronger revenue mix. EnSilica’s partnerships with TSMC and GlobalFoundries and its ITAR-free European supply chain position it to capitalise on rising demand for regionally sourced ASICs. Strong progress continues in satellite communications and EV-compatible automotive ASICs, supported by feasibility studies, chip sampling, and expanded engineering teams in Budapest and Cambridge. The company maintains cash discipline with no new equity issuance planned and targets sustainable EBITDA and revenue growth through FY26.

Focusrite PLC (TUNE:LSE) delivered a robust investor update for the 12 months to August 2024, showcasing resilient financial performance, strong revenue momentum, and continued innovation across its Content Creation and Audio Reproduction divisions. CEO Tim Carroll and CFO Sally McKone reported solid growth across all brands in Content Creation, underpinned by successful new product launches, strengthening EMEA and APAC markets, and a recovery in U.S. demand. The group achieved a gross margin of 44.4% and an EBITDA margin of 14.6%, reflecting disciplined cost control and effective pricing actions that offset U.S. tariff pressures. Net debt reduced to £10.8 million, supported by a return to positive free cash flow of £5.8 million. Focusrite’s Audio Reproduction segment normalized after exceptional post-pandemic demand, with 37 in-house product launches and continued organizational efficiency driving operational leverage. The company reported sustained end-user registrations and leading market share positions across major distributors such as Thomann and Sweetwater, while strategic acquisitions like TiMax expanded its addressable live sound market to nearly 100%. Management emphasized investment in R&D, AI integration to boost customer insight and workflow efficiency, and ongoing enhancement of direct-to-consumer e-commerce channels. Despite inflationary pressures and higher import costs, Focusrite maintained stable margins and expects to deliver medium- to high-single-digit organic growth, margin resilience within the 45–47% range, and steady cash generation. With a diversified brand portfolio, global reach, and clear focus on innovation, efficiency, and customer engagement, Focusrite remains well positioned for long-term, profitable growth and strong shareholder returns.

India Capital Growth Fund Limited (IGC:LSE) delivered an in-depth investor presentation highlighting its 20-year track record, strategic focus on India’s mid and small-cap equity markets, and long-term value creation approach. Principal adviser Gaurav Narain detailed India’s macroeconomic transformation, driven by demographic strength, political stability, digital infrastructure, and consistent reforms under the Modi-led government. India’s economy, now the world’s fourth largest at $4 trillion, is projected to sustain real GDP growth of 6–7% with rising consumption, infrastructure investment, and corporate capex. Despite temporary headwinds—including tightened liquidity, inflation, and trade tariffs—the outlook remains robust with fiscal deficit reduction, record forex reserves, and improving earnings growth. The fund’s portfolio is built around quality management, free cash flow generation, and high return on capital, with core holdings in consistent compounders such as PI Industries and Balkrishna Industries. Currently, 67% of holdings are in small caps and over 60% of the portfolio has been held for more than five years, reflecting its disciplined, bottom-up approach. The trust has outperformed the MSCI India Index over the long term and compounded at roughly 13.5% annually since 2011. Management reaffirmed its confidence in India’s long-term growth story and the fund’s positioning to benefit from continued economic expansion, digital acceleration, and increasing domestic investment flows.

ReFuels CEO and CFO will present a company update following a successful debt financing process to progress the company´s BioCNG station rollout

Biotech Growth Trust PLC (BIOG:LSE) delivered an upbeat investor presentation outlining strong recent performance and a renewed bullish outlook for the biotechnology sector. Co-portfolio managers Josh Golomb and Geoffrey Hsu of OrbiMed highlighted the trust’s six-month NAV gain of 37%, far outpacing the NASDAQ Biotech Index’s 10.5% rise, driven by successful small-cap positioning. The managers emphasized OrbiMed’s $19 billion AUM and deep healthcare expertise, underscoring confidence in biotech’s recovery after years of sector-wide underperformance. They cited historically low valuations, robust M&A momentum, and easing macroeconomic pressures such as stabilizing interest rates as major catalysts for growth. Key themes included transformative breakthroughs in oncology, autoimmune, and CNS therapies, alongside FDA approvals of innovative drugs from companies such as Gilead and Vertex. The trust also benefits from exposure to emerging biotech innovation in China, aided by OrbiMed’s on-the-ground analysts in Shanghai and Hong Kong. Despite recent political uncertainty in the U.S., management expressed optimism in a pro-innovation environment under the Trump administration and a strong FDA approval pace. Looking ahead, Biotech Growth Trust aims to maintain gearing between 5–10%, continue favoring small- and mid-cap exposure, and capitalize on the widening valuation gap between biotech fundamentals and market pricing, positioning itself for significant upside as the sector rebounds.

Wynnstay Properties PLC (WSP:AIM) reported a robust investor update for the six months ended 29 September 2025, highlighting continued portfolio strength and steady income growth. Rental and property income rose 2.8% to £1.4m, supported by the strategic acquisition of a property in Waterbeach, Cambridge, while operating income dipped 6.4% to £1m due to refurbishment and lease renewal costs. Net asset value per share increased 2.7% to 1,173p, and the interim dividend was raised 5% to 10.5p per share, reflecting Wynnstay’s progressive dividend policy. Borrowings stood at £11.4m with £3.6m of undrawn credit under its revolving facility, underpinned by ongoing support from Handelsbanken and Dupart Finance. Leasing performance remained strong, with nine new leases agreed at higher rents, 99% rent collection, and minimal vacancy of just 0.4%. The company continues to invest in sustainability, budgeting approximately £200,000 to upgrade properties to EPC ratings of C or higher by 2030. It is also exploring development opportunities at Ipswich, Aylesford, and Liphook to enhance long-term income and capital growth. Management expressed confidence in the business outlook, citing stable yields around 6.5%, excellent tenant retention, and resilient demand across its quality commercial property portfolio. This investor update underscores Wynnstay Properties PLC’s disciplined growth strategy, sound financial management, and commitment to delivering sustainable value for shareholders despite a challenging economic backdrop.